Reports FY23 revenue $39.019M, consensus $38.96M. "In 2022 we focused on three key initiatives: exploring several combination therapies with AB-729, our RNAi therapeutic, as a potential cornerstone agent in a functional cure for hepatitis B virus; advancing our preclinical HBV compounds AB-101, our oral PD-L1 inhibitor, and AB-161, our oral RNA destabilizer; and identifying a clinical candidate that inhibits the SARS-CoV-2 nsp5 main protease," said William Collier, Arbutus’ President and Chief Executive Officer. "With promising AB-729 data in-hand and plans to initiate phase 1 clinical trials with AB-101, AB-161 and our newly nominated pan-coronavirus Mpro compound, AB-343, we achieved our 2022 corporate objectives and are now well-positioned to further execute on these strategic initiatives to deliver multiple clinical milestones this year. The need for a functional cure for patients with cHBV and alternatives to treat COVID-19 and future coronavirus outbreaks remains urgent, and we look forward to advancing our pipeline to address these large global market opportunities."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABUS:
- Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- SVB downgrades Moderna to Underperform as COVID boom reverses
- Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
- Arbutus Biopharma management to meet with Piper Sandler